Novocure Shares Rise After Co Boosts FY26 Revenue Guidance

Dow Jones07-23

Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.

The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year.

Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier.

Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million.

Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability.

Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 23, 2026 10:03 ET (14:03 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653725705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-23 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653725705","market":"nz","top_or_hot":-1,"title":"Novocure Shares Rise After Co Boosts FY26 Revenue Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novocure Shares Rise After Co Boosts FY26 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovocure Shares Rise After Co Boosts FY26 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-23 22:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n</p>\n<p>\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n</p>\n<p>\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n</p>\n<p>\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n</p>\n<p>\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n</p>\n<p>\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2026 10:03 ET (14:03 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2653725705","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653725705","pubTimestamp":1784815380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter.The stock was up 26% to $19.59 in recent tr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","NVCR":"NovoCure Limited"},"translate_title":"公司上调 26 财年收入指引后，Novocure 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":0.9},"content_text":"Shares of Novocure rose after the global oncology company raised its fiscal 2026 revenue guidance, as sales rose and its loss narrowed in the second quarter. \n\n\n  The stock was up 26% to $19.59 in recent trading, and rose 51% since the start of the year. \n\n\n  Novocure reported a loss of $15.7 million, or 13 cents a share, compared with a loss of $40.1 million, or 36 cents a share, a year earlier. \n\n\n  Revenue rose 16% to $183.6 million. Analysts polled by FactSet expected $172.4 million. \n\n\n  Chief Executive Frank Leonard said the company would continue to launch therapies in multiple markets. He added Novocure was well-positioned to drive sustainable growth and make material progress toward profitability. \n\n\n  Novocure raised its fiscal 2026 revenue guidance to between $710 million and $725 million from its previous guidance of between $690 million and $710 million. Analysts polled by FactSet were expecting $708.7 million. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2026 10:03 ET (14:03 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653725705","isCrawlerRequest":true}